June 8, 2023 10:49 AM EDT
FDA+

FDA ac­cepts an­oth­er sBLA for Mer­ck­'s Keytru­da, fol­low­ing Imfinzi in bil­iary tract can­cer

Paul Schloesser

Associate Editor

Mer­ck an­nounced Thurs­day morn­ing that the FDA has ac­cept­ed an sBLA for its sales king­pin and an­ti-PD-1 ther­a­py Keytru­da, set­ting a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Genen­tech vet launch­es ADC start­up with $20M

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times